Small Molecule Inhibitors of the Yersinia Type III Secretion System Impair the Development of Chlamydia After Entry into Host Cells

Overview

Journal BMC Microbiol

Publisher Biomed Central

Specialty Microbiology

Date 2009 Apr 23

PMID 19383140

Citations 24

Authors

Sandra Muschiol

Staffan Normark

Birgitta Henriques-Normark

Agathe Subtil

Affiliations

Soon will be listed here.

Abstract

Background: Chlamydiae are obligate intracellular pathogens that possess a type III secretion system to deliver proteins into the host cell during infection. Small molecule inhibitors of type III secretion in Yersinia, termed INPs (Innate Pharmaceuticals AB) were reported to strongly inhibit Chlamydia growth in epithelial cells. In this study we have analyzed the effect of these drugs on bacterial invasiveness.

Results: We demonstrate that INPs affect Chlamydia growth in a dose dependent manner after bacterial invasion. The efficiency of C. trachomatis L2 and C. caviae GPIC entry into host cells was not altered in the presence of INPs. In C. caviae, entry appears to proceed normally with recruitment of actin and the small GTPases Rac, Cdc42 and Arf6 to the site of bacterial entry.

Conclusion: INPs have a strong inhibitory effect on Chlamydia growth. However, bacterial invasion is not altered in the presence of these drugs. In the light of these results, we discuss several hypotheses regarding the mode of action of INPs on type III secretion during the Chlamydia infectious cycle.

Citing Articles

CT584 Is Not a Protective Vaccine Antigen against Respiratory Chlamydial Challenge in Mice.

Hoang-Phou S, Pal S, Slepenkin A, Abisoye-Ogunniyun A, Zhang Y, Gilmore S Vaccines (Basel). 2024; 12(10).

PMID: 39460301 PMC: 11512284. DOI: 10.3390/vaccines12101134.

Beyond Antibiotics: What the Future Holds.

Benyamini P Antibiotics (Basel). 2024; 13(10).

PMID: 39452186 PMC: 11504868. DOI: 10.3390/antibiotics13100919.

Evaluation in mice of cell-free produced CT584 as a Chlamydia vaccine antigen.

Hoang-Phou S, Pal S, Slepenkin A, Abisoye-Ogunniyun A, Zhang Y, Gilmore S bioRxiv. 2024; .

PMID: 38895407 PMC: 11185655. DOI: 10.1101/2024.06.04.597210.

Type III Secretion in .

Rucks E Microbiol Mol Biol Rev. 2023; 87(3):e0003423.

PMID: 37358451 PMC: 10521360. DOI: 10.1128/mmbr.00034-23.

Antimicrobial Resistance and Recent Alternatives to Antibiotics for the Control of Bacterial Pathogens with an Emphasis on Foodborne Pathogens.

Helmy Y, Taha-Abdelaziz K, Hawwas H, Ghosh S, Sami Alkafaas S, Moawad M Antibiotics (Basel). 2023; 12(2).

PMID: 36830185 PMC: 9952301. DOI: 10.3390/antibiotics12020274.

References

Betts H, Twiggs L, Sal M, Wyrick P, Fields K . Bioinformatic and biochemical evidence for the identification of the type III secretion system needle protein of Chlamydia trachomatis. J Bacteriol. 2008; 190(5):1680-90. PMC: 2258694. DOI: 10.1128/JB.01671-07. View

Muschiol S, Bailey L, Gylfe A, Sundin C, Hultenby K, Bergstrom S . A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A. 2006; 103(39):14566-71. PMC: 1566191. DOI: 10.1073/pnas.0606412103. View

Ouellette S, AbdelRahman Y, Belland R, Byrne G . The Chlamydia pneumoniae type III secretion-related lcrH gene clusters are developmentally expressed operons. J Bacteriol. 2005; 187(22):7853-6. PMC: 1280318. DOI: 10.1128/JB.187.22.7853-7856.2005. View

SHAW E, Dooley C, Fischer E, Hackstadt T . Identification and characterization of a Chlamydia trachomatis early operon encoding four novel inclusion membrane proteins. Mol Microbiol. 1999; 33(4):753-65. DOI: 10.1046/j.1365-2958.1999.01523.x. View

Clifton D, Fields K, Grieshaber S, Dooley C, Fischer E, MEAD D . A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc Natl Acad Sci U S A. 2004; 101(27):10166-71. PMC: 454183. DOI: 10.1073/pnas.0402829101. View

Scidmore M, Rockey D, Fischer E, Heinzen R, Hackstadt T . Vesicular interactions of the Chlamydia trachomatis inclusion are determined by chlamydial early protein synthesis rather than route of entry. Infect Immun. 1996; 64(12):5366-72. PMC: 174531. DOI: 10.1128/iai.64.12.5366-5372.1996. View

Dautry-Varsat A, Subtil A, Hackstadt T . Recent insights into the mechanisms of Chlamydia entry. Cell Microbiol. 2005; 7(12):1714-22. DOI: 10.1111/j.1462-5822.2005.00627.x. View

Lane B, Mutchler C, Al Khodor S, Grieshaber S, Carabeo R . Chlamydial entry involves TARP binding of guanine nucleotide exchange factors. PLoS Pathog. 2008; 4(3):e1000014. PMC: 2279300. DOI: 10.1371/journal.ppat.1000014. View

Slepenkin A, Enquist P, Hagglund U, de la Maza L, Elofsson M, Peterson E . Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun. 2007; 75(7):3478-89. PMC: 1932962. DOI: 10.1128/IAI.00023-07. View

10.

Jewett T, Dooley C, Mead D, Hackstadt T . Chlamydia trachomatis tarp is phosphorylated by src family tyrosine kinases. Biochem Biophys Res Commun. 2008; 371(2):339-44. PMC: 2394672. DOI: 10.1016/j.bbrc.2008.04.089. View

11.

Bailey L, Gylfe A, Sundin C, Muschiol S, Elofsson M, Nordstrom P . Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 2007; 581(4):587-95. DOI: 10.1016/j.febslet.2007.01.013. View

12.

Bavoil P, Hsia R . Type III secretion in Chlamydia: a case of déjà vu?. Mol Microbiol. 1998; 28(4):860-2. DOI: 10.1046/j.1365-2958.1998.00861.x. View

13.

Nordfelth R, Kauppi A, Norberg H, Wolf-Watz H, Elofsson M . Small-molecule inhibitors specifically targeting type III secretion. Infect Immun. 2005; 73(5):3104-14. PMC: 1087345. DOI: 10.1128/IAI.73.5.3104-3114.2005. View

14.

Cornelis G . The type III secretion injectisome. Nat Rev Microbiol. 2006; 4(11):811-25. DOI: 10.1038/nrmicro1526. View

15.

Rockey D, Heinzen R, Hackstadt T . Cloning and characterization of a Chlamydia psittaci gene coding for a protein localized in the inclusion membrane of infected cells. Mol Microbiol. 1995; 15(4):617-26. DOI: 10.1111/j.1365-2958.1995.tb02371.x. View

16.

Balana M, Niedergang F, Subtil A, Alcover A, Chavrier P, Dautry-Varsat A . ARF6 GTPase controls bacterial invasion by actin remodelling. J Cell Sci. 2005; 118(Pt 10):2201-10. DOI: 10.1242/jcs.02351. View

17.

Fields K, Hackstadt T . Evidence for the secretion of Chlamydia trachomatis CopN by a type III secretion mechanism. Mol Microbiol. 2000; 38(5):1048-60. DOI: 10.1046/j.1365-2958.2000.02212.x. View

18.

Carabeo R, Grieshaber S, Fischer E, Hackstadt T . Chlamydia trachomatis induces remodeling of the actin cytoskeleton during attachment and entry into HeLa cells. Infect Immun. 2002; 70(7):3793-803. PMC: 128046. DOI: 10.1128/IAI.70.7.3793-3803.2002. View

19.

Subtil A, Wyplosz B, Balana M, Dautry-Varsat A . Analysis of Chlamydia caviae entry sites and involvement of Cdc42 and Rac activity. J Cell Sci. 2004; 117(Pt 17):3923-33. DOI: 10.1242/jcs.01247. View

20.

Carabeo R, Grieshaber S, Hasenkrug A, Dooley C, Hackstadt T . Requirement for the Rac GTPase in Chlamydia trachomatis invasion of non-phagocytic cells. Traffic. 2004; 5(6):418-25. DOI: 10.1111/j.1398-9219.2004.00184.x. View